Lu Xie

Deputy Medical Director
Musculoskeletal Tumor Centre, Peking University People's Hospital
Beijing, Beijing, China (People's Republic)

Lu Xie
Medical and Pediatric Oncologist for Sarcoma
Deputy Medical Director, Musculoskeletal Tumor Center
Clinical Associate Professor, Master supervisor, Peking University
She conducted many trials for target therapy for advaced osteosarcoma, such as apatinib or Apatinib plus
camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial and so on. She would much love to devote herself into the tumor microenviroment for osteosarcoma.

Presentation(s):

• Paper 07 - ARTEMIS-002: A PHASE 2 STUDY OF HS-20093 IN PATIENTS WITH RELAPSED OR REFRACTORY SARCOMAS

  Thursday, November 13, 2025
  11:30 AM - 12:30 PM EST

  Disclosure information not submitted.